VOXZOGO (BioMarin Pharmaceutical Australia Pty Ltd)
Product name
VOXZOGO
Date registered
Evaluation commenced
Decision date
Approval time
117 (255 working days)
Active ingredients
vosoritide
Registration type
NCE/NBE
Indication
VOXZOGO is indicated for the treatment of achondroplasia in patients 2 years of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.